ClinicalTrials.gg
RecruitingNCT06170970SOLARIMSUpdated Jun 9, 2026

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

A Phase 2 interventional study of Solriamfetol and Placebo in Multiple Sclerosis and Multiple Sclerosis Fatigue, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Johns Hopkins University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Multiple Sclerosis by Johns Hopkins University — 4 open to participants now, 5 under way, none of them phase 3. Multiple Sclerosis · Johns Hopkins University.

Planned enrollment
10th of 18
46 · median 48
Started
2024
the only one that year
Phase 2
4 of 20
2 open now
Registered
18th of 20
by date

Among the 20 studies in Multiple Sclerosis by Johns Hopkins University, this one is the 10th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2024, is one of 4 in phase 2, and was the 18th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

4 of the 20 studies in Multiple Sclerosis by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Multiple Sclerosis by Johns Hopkins University, or all of them as a file.
02

Study summary

Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatments, including off-label prescriptions of wake-promoting agents, have shown limited effectiveness. Previous research indicates that these agents may be beneficial specifically for MS patients with concomitant excessive daytime sleepiness. This study uses a randomized, double-blind, placebo-controlled crossover design. Participants will undergo a 10-day lead-in with he medication/placebo, followed by two four-week treatment periods separated by a one-week washout. Outcomes will be measured primarily using the Modified Fatigue Impact Scale (MFIS), with additional exploratory measures collected via a smartphone app that assesses fatigue through keystroke dynamics. This novel approach to fatigue measurement aims to capture real-time variations and provide more granular data than traditional self-report questionnaires.

03

Conditions studied

  • Multiple Sclerosis
  • Multiple Sclerosis Fatigue

Keywords

  • multiple sclerosis
  • fatigue
  • daytime sleepiness
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 to 60 years of age, inclusive.
  • Medically stable on the basis of physical examination, medical history, and vital signs
  • Must meet McDonald 2024 diagnostic criteria for multiple sclerosis based on the PI review of the medical records
  • Must complain from fatigue as one of their main symptoms and have a screening MFIS score of 33 or more
  • A screening ESS score of 10 or more
  • Must be ambulatory (able to walk at least 20 feet using bilateral assistance)
  • Must have internet and email access and the ability to use a computer or tablet, or smartphone
  • Own an android smartphone or an iphone
  • Consent to use a medically acceptable method of for the duration of the study
  • Willing and able to comply with the study design schedule and other requirements
  • Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • History of coronary artery disease or congestive heart failure
  • Uncontrolled hypertension at Screening (history of high blood pressure and screening systolic blood pressure >160 or diastolic blood pressure>100)
  • A known history of uncontrolled diabetes (the last known level above 7.0%), high (>35), or hyperlipidemia (last known total cholesterol >240 mg/dl, or LDL cholesterol level >160 mg/dl)
  • Receiving drugs/treatments that increase blood pressure or heart rate (based on the PI review of the medications/treatments)
  • A history of cerebrovascular disease or stroke
  • A medical or neurological disorder other than MS, that was associated with excessive sleepiness.
  • A history of phenylketonuria or to the phenylalanine-derived product
  • A history of alcohol or drug abuse within the past two years
  • A history of psychosis, or bipolar disorder
  • A history of cardiac arrythmias
  • The use of any product with stimulating or sedating properties, unless they have been on a steady dose for at least a month prior to the screening visit and agree to stay on the same dose over the course of the study
  • Use within 14 days of a monoamine oxidase (MAO) inhibitor drug
  • Pregnant or lactating
  • Use of medications used for the treatment of fatigue (including amantadine, modafinil, armodafinil, and amphetamine-like stimulants) in the past two weeks of the screening visit
  • A known history of moderate or severe kidney dysfunction (estimated of less than 60 mL/min)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    solriamfetol then placebo first

    Four weeks of treatment with solriamfetol followed by one week of washout and four weeks of treatment with placebo

    Drug: Solriamfetol · Drug: Placebo

  • Experimental
    placebo then solriamfetol first

    Four weeks of treatment with placebo followed by one week of washout and four weeks of treatment with solriamfetol

    Drug: Solriamfetol · Drug: Placebo

Interventions

  • solriamfetol 75 mg daily for 3 days and will increase the dose to 150 mg daily starting on day 4 of the treatment period (total of four weeks)

    Also known as: Sunosi

  • DrugPlacebo

    Four weeks of oral placebo

06

What researchers measure

Primary outcomes

  1. Modified Fatigue Impact Scale (MFIS) Score

    MFIS score measured during the last three days of each 4-week medication period. The total score of the MFIS ranges from 0 to 84. Higher scores denote more severe fatigue.

    Time frame: Up to 4 weeks

Secondary outcomes

  1. Fatigue Severity Scale (FSS) Score

    FSS score measured during the last three days of each 4-week medication period. The total score of the FSS ranges from 1 to 7. Higher scores denote more severe fatigue.

    Time frame: Up to 4 weeks

  2. Epworth Sleepiness Scale (ESS) Score

    ESS score measured during the last three days of each 4-week medication period. The total score of the ESS ranges from 0 to 24. Higher scores denote more severe daytime sleepiness.

    Time frame: Up to 4 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The investigators have set a timeline for data availability, commencing one year after the publication of the trial's main findings and extending for a period of five years. This timeframe ensures data relevance while providing ample opportunity for research exploration. Access to the data will be governed by a stringent but fair set of criteria. Interested researchers must submit a methodologically sound proposal, which will be evaluated by an independent review panel. This process ensures that the data are used to pursue scientifically valuable and ethically sound objectives. Researchers accessing the data must agree to terms that uphold privacy, ensure data security, and prohibit the further sharing of data with third parties.

Supporting information: Study protocol, Statistical analysis plan

Time frame: one year after the publication of the main trial results to 5 years after the publication.

Access criteria: Researchers accessing the data must agree to terms that uphold privacy, ensure data security, and prohibit the further sharing of data with third parties.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

Of 49 non-industry phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 68. This study's planned 30 months is below that.

Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 20 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2023
First posted
Dec 14, 2023
StartActual
Jun 1, 2024
Primary completionEst.
Dec 1, 2026
CompletionEst.
Mar 1, 2027
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06170970
Collaborators
National Multiple Sclerosis Society, Axsome Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 14, 2023
Start date
Jun 1, 2024
Primary completion
Dec 1, 2026 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Jun 9, 2026

Study contacts

Lauren Vega, BSN
Contact
Ldimarc2@jhmi.edu
410-614-1522
Bardia Nourbakhsh, MD
principal investigator · Johns Hopkins School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solriamfetol

Start the discussion